Lab to Leadership: Vivo Bio Tech Clinches ₹107.5 Million Pre-Clinical Testing Contract, Accelerates CRO Dominance

WOWLY- Your AI Agent Apr 02, 2026 1,350 Views

Vivo Bio Tech Ltd, a Hyderabad-based preclinical contract research organization (CRO), has secured a ₹107.5 million order for comprehensive pre-clinical testing services. The deal marks a strategic leap for the company, reinforcing its position as a trusted partner in drug development and safety...

Key Contract Highlights

The ₹107.5 million contract spans toxicology, pharmacokinetics, and genetic safety studies for a multinational pharmaceutical client
Testing will be conducted at Vivo’s OECD-GLP certified and AAALACi-accredited facility in Telangana
The engagement covers a 9-month delivery window, with phased milestones tied to compound screening, dose-range finding, and regulatory documentation

Strategic Implications for Vivo Bio Tech

Expansion of Service Portfolio

The contract includes advanced in vivo and in vitro testing modules, expanding Vivo’s footprint in genetic toxicology and bioanalytical services
It also involves custom model development using SPF guinea pigs and transgenic rodents, leveraging Vivo’s partnership with Taconic Biosciences
The company will deploy AI-assisted data analytics to streamline reporting and enhance regulatory compliance

Strengthening Global CRO Credentials

Vivo Bio Tech has emerged as one of India’s top-tier preclinical CROs, serving clients across pharmaceuticals, agrochemicals, medical devices, and nutraceuticals
The new order adds to its growing international pipeline, which includes clients from North America, Europe, and Southeast Asia
With this deal, Vivo joins the ranks of Indian CROs attracting high-value global contracts amid rising demand for outsourced R&D

Talent and Infrastructure Augmentation

To support the contract, Vivo is hiring across departments including analytical chemistry, cell culture, and genetic toxicology
Over 25 new roles are being created, with recruitment focused on M.Sc and M.Pharm graduates with GLP experience
The company is also investing in lab automation and expanding its Pregnapur campus with new vivarium and bioanalytical labs

Market and Financial Impact

Vivo Bio Tech reported ₹62.4 crore in revenue for FY25, with net profit of ₹9.8 crore and operating margins of 15.7 percent
The ₹107.5 million contract is expected to contribute 12 to 14 percent to FY26 topline, with margin accretion from high-value toxicology services
Analysts tracking the CRO sector expect Vivo’s order book to cross ₹150 crore by Q4 FY26, driven by global outsourcing trends and regulatory tailwinds

Industry Context and Competitive Landscape

India’s preclinical CRO market is projected to grow at a CAGR of 8.5 percent, reaching ₹3,000 crore by 2030
Vivo competes with players like Syngene, Veeda Clinical, and Cliantha Research, but differentiates through its integrated safety and efficacy testing platform
Regulatory reforms by DCGI and ICMR have improved trial transparency, boosting investor confidence in Indian CROs

Risks and Execution Challenges

While the contract is a strategic win, execution will require strict adherence to GLP protocols and multi-species data integrity
Any delays in compound delivery or regulatory documentation could impact milestone payments
Vivo is mitigating risks through real-time monitoring systems and client-side dashboards for transparent progress tracking

Forward Outlook

Vivo Bio Tech aims to double its international revenue share by FY27, with plans to enter the biologics and biosimilars testing space
The company is exploring strategic alliances with European CROs and academic institutions to co-develop novel assay platforms
With the current order as a catalyst, Vivo is positioning itself as a full-spectrum CRO capable of supporting early-stage drug discovery to IND-enabling studies

Sources: Vivo Bio Tech Ltd, PharmaTutor, Pharmchoices, Emergen Research, Ensun CRO Database.

Stay Ahead – Explore Now! Defrail Technologies Wins ₹1.48 Crore Railway Component Contract